



# Expanding blood-based risk assessment offerings with LifeLabs® Apolipoprotein (ApoE) Isoform

Our LifeLabs® blood-based Alzheimer's disease (AD) risk assessment portfolio includes testing for ApoE isoforms.

LifeLabs® is committed to expanding the Alzheimer's portfolio of AD and dementia test offerings to support you and your patients through blood-based, easily accessible risk assessment options that can directly impact your care pathway.



Apolipoprotein E (ApoE), the primary brain apolipoprotein, is a biomarker for AD that can be found in the blood or cerebrospinal fluid (CSF).



About half of AD patients carry the E4 allele, compared with 15% in the general population.<sup>1</sup>



Genetic counselling support is included with ApoE testing. A genetic counsellor may be very helpful in fully understanding the implications of a patient's genetic results, their potential impact on their health, and any necessary next steps. A genetic counsellor can be reached at 1-844-363-4357 or [Ask.Genetics@LifeLabs.com](mailto:Ask.Genetics@LifeLabs.com)



The presence of an E4 allele is associated with both increased disease risk and decreased average age of onset compared with E2 or E3 alleles.<sup>2</sup>



This test can be ordered alongside other tests in the LifeLabs Alzheimer's portfolio, such as LifeLabs p-tau217 and Amyloid Beta 42/40, for a more robust risk assessment.



Knowledge of ApoE isoform status is required for patients considering amyloid-modifying therapies due to the risk of amyloid-related imaging abnormalities (ARIA).

Test code (ON)	Test name	Turnaround time	Volume
5638	LifeLabs® Apolipoprotein E (ApoE) Isoform, Plasma	12 days	1 mL (0.5 mL minimum)

Visit [LifeLabs.com/alzheimers-disease](https://www.lifelabs.com/alzheimers-disease) to learn more about our portfolio or [click here](#) to download requisition.

To receive the latest news and updates from LifeLabs, please join our email list by clicking the 'sign up' button.

[Sign up](#)

Patient sex, environment, race, ethnicity, and presence of other risk alleles also contribute to the risk of AD associated with ApoE genotype.<sup>3</sup>

## References

1. Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/e4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. *Neuroepidemiology*. 2012;38(1):1-17. doi:10.1159/000334607
2. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. *Neuron*. 2009; 63(3):287-303. doi:10.1016/j.neuron.2009.06.026
3. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. *JAMA*. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041

Test codes may vary by location. Please contact your local laboratory for more information.